Hexarelin Preserves Cardiac Function After Ischemia-Reperfusion Injury by Reducing Inflammation and Fibrosis in Mice
Background
Myocardial ischemia-reperfusion injury (IRI) is a major cause of heart damage following events like a heart attack, where blood flow is restored. Despite advanced reperfusion therapies (like angioplasty or stents), preventing this secondary injury remains a significant clinical challenge, leading to adverse cardiac remodeling and heart failure. Growth hormone secretagogues (GHS), a class of compounds that includes hexarelin, have shown promise in improving cardiac function and reducing inflammation in other cardiovascular disease models. This study investigates hexarelin in a reperfused ischemic model, which more closely mimics the clinical scenario of acute myocardial infarction treatment, to see if its previously observed cardioprotective effects hold true.
Study Design
The study used a mouse model of myocardial ischemia-reperfusion injury. C57BL/6J mice underwent transient ligation of the left descending coronary artery (tLAD) to induce ischemia. Immediately before reperfusion, mice were treated with either Hexarelin (0.3 mg/kg/day; n=20) or a vehicle control (VEH; n=18) for 21 days. A sham-operated group was also included. Left ventricular (LV) function was assessed using high-field magnetic resonance imaging. Researchers also measured markers of cardiac fibrosis, inflammation, and autonomic nervous system balance.
Results
Hexarelin treatment resulted in significant cardioprotection. Mice receiving hexarelin demonstrated a significant improvement in left ventricular (LV) function compared to the vehicle-treated group after 21 days. The treatment also led to a significant decrease in interstitial collagen, TGF-β1 expression, and myofibroblast differentiation, indicating a reduction in adverse cardiac remodeling and fibrosis.
Furthermore, hexarelin administration produced a significant decrease in cardiac troponin-I and
TNF-αlevels, suggesting a potent anti-inflammatory effect on the damaged myocardium.
The study also found that hexarelin shifted the autonomic nervous system balance towards a parasympathetic predominance. The authors suggest that hexarelin activates vagal anti-inflammatory pathways to prevent adverse remodelling and LV dysfunction following ischemia-reperfusion injury.
Key Findings
- Hexarelin (0.3 mg/kg/day for 21 days) significantly improved left ventricular function in mice post-IRI.
- Treatment significantly decreased interstitial collagen, TGF-β1 expression, and myofibroblast differentiation.
- Hexarelin significantly lowered levels of cardiac troponin-I and the inflammatory cytokine TNF-α.
- The peptide shifted autonomic balance towards a parasympathetic predominance, suggesting vagal pathway activation.
- The study provides evidence for hexarelin's translational potential in treating acute myocardial infarction.
Why It Matters
This research provides compelling evidence for hexarelin as a potential therapeutic agent to mitigate heart damage following a heart attack. For individuals interested in cardiac recovery protocols, hexarelin demonstrates a multi-faceted mechanism, simultaneously improving heart function, reducing scar tissue formation (fibrosis), and combating inflammation. The study highlights its action on the autonomic nervous system, suggesting it may work by activating the body's own anti-inflammatory 'vagal' pathways. While many interventions for IRI have failed in clinical trials, this study's use of a clinically relevant model and its positive outcomes suggest a promising path for translation. However, this is an animal study, and human trials would be necessary to establish safety, dosing, and efficacy in patients.
hexarelin
cardioprotection
myocardial infarction
ischemia-reperfusion injury
cardiovascular
inflammation
